Activity of fludarabine in previously treated Waldenström's macroglobulinemia: a report of 71 cases. Groupe Coopératif Macroglobulinémie.
Fiche publication
Date publication
juin 1998
Journal
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr DECONINCK Eric, Pr DELMER Alain
Tous les auteurs :
Leblond V, Ben-Othman T, Deconinck E, Taksin AL, Harousseau JL, Delgado MA, Delmer A, Maloisel F, Mariette X, Morel P, Clauvel JP, Duboisset P, Entezam S, Hermine O, Merlet M, Yakoub-Agha I, Guibon O, Caspard H, Fort N
Lien Pubmed
Résumé
There is no consensus on the treatment of patients with Waldenström's macroglobulinemia (WM) who develop primary or secondary resistance to frontline therapies. We report our experience on the activity and toxicity of fludarabine in 71 patients with WM resistant to prior chemotherapy regimens.
Mots clés
Adult, Aged, Aged, 80 and over, Blood Cell Count, Drug Resistance, Humans, Immunoglobulin M, blood, Immunosuppressive Agents, adverse effects, Middle Aged, Retrospective Studies, Survival Rate, Time Factors, Treatment Outcome, Vidarabine, adverse effects, Waldenstrom Macroglobulinemia, drug therapy
Référence
J. Clin. Oncol.. 1998 Jun;16(6):2060-4